Hot Spots Where Covid Vaccination Lags Push Experimental Antibody Treatment

(By JoNel Aleccia for Kaiser Health News)

For months, Joelle Ruppert was among the millions of Americans who are covid vaccine holdouts. Her reluctance, she said, was not so much that she opposed the new vaccines but that she never felt “compelled” by the evidence supporting their experimental use.

Nonetheless, after she fell ill with covid last month, Ruppert, a Florida preschool teacher, found herself desperate to try an experimental product that promised to ease her symptoms: infusion with a potent laboratory-produced treatment known as monoclonal antibody therapy.  Continue reading the article here…

Kaiser Health News is a nonprofit national health policy news service that is part of the nonpartisan Henry J. Kaiser Family Foundation

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org